Patents by Inventor Nikolaus Osterrieder
Nikolaus Osterrieder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9555101Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising the recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.Type: GrantFiled: November 17, 2014Date of Patent: January 31, 2017Assignee: Merial, Inc.Inventors: Jean Christophe Audonnet, Jules Maarten Minke, Nikolaus Osterrieder, Guanggang Ma
-
Publication number: 20150190502Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.Type: ApplicationFiled: November 17, 2014Publication date: July 9, 2015Applicant: MERIAL LIMITEDInventors: Jean Christophe Audonnet, Jules Maarten Minke, Nikolaus Osterrieder, Guanggang Ma
-
Patent number: 8916371Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.Type: GrantFiled: March 15, 2013Date of Patent: December 23, 2014Assignee: Merial LimitedInventors: Jean Christophe Audonnet, Jules Maarten Minke, Nikolaus Osterrieder, Guanggang Ma
-
Patent number: 8637046Abstract: The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host. In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through co-administration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease. In one example, use of the modified BHV-1 in the administered compositions facilitates an immune response to or against the additional immunogens.Type: GrantFiled: October 1, 2009Date of Patent: January 28, 2014Assignees: Cornell University, Novartis AGInventors: Nikolaus Osterrieder, Benedikt B. Kaufer, Gopinath Raju Seetharaman, Richard Harland, Lee David Albee, II, Mayur Navnitbhai Patel
-
Publication number: 20130251747Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.Type: ApplicationFiled: March 15, 2013Publication date: September 26, 2013Applicants: FREIE UNIVERSITÄT BERLIN, MERIAL LIMITEDInventors: Jean Christophe Audonnet, Jules Maarten Minke, Nikolaus Osterrieder, Guanggang Ma
-
Publication number: 20130195918Abstract: We have constructed a mutant EHV-1 that is lacking the entire 12.7 kbp IR segment of the viral genome and found the mutant EHV-1 to be replication competent, to have the ability to replicate in mammalian cell types (including human cells), and to exhibit reduced virulence in the mouse model of EHV-1 virulence.Type: ApplicationFiled: August 2, 2012Publication date: August 1, 2013Inventors: Dennis J. O'Callaghan, ByungChul Ahn, Yunfei Zhang, Nikolaus Osterrieder
-
Publication number: 20120034262Abstract: The disclosure relates generally to the treatment or prevention of disease in cattle. More particularly, the invention is directed to the production and use of modified bovine herpesvirus 1 (BHV-1) and their use in compositions and vaccines that protect cattle from BHV-1 infection while not suppressing the immunological response in the host. In one example, the invention is directed to the use of modified BHV-1, administered with additional immunogens, either through co-administration and/or through administration in combination vaccines, and the use of these vaccines for the protection of cattle from disease. In one example, use of the modified BHV-1 in the administered compositions facilitates an immune response to or against the additional immunogens.Type: ApplicationFiled: October 1, 2009Publication date: February 9, 2012Applicants: NOVARTIS AG, CORNELL UNIVERSITYInventors: Nikolaus Osterrieder, Benedikt B. Kaufer, Gopinath Raju Seetharaman, Richard Harland, Lee David Albee, II, Mayur Navnitbhai Patel
-
Patent number: 8017317Abstract: This invention relates to Equine Herpes Viruses (EHV) wherein the protein gM is essentially absent or modified and non-functional with respect to its immunomodulatory capacity. Further aspects of the invention relate to nucleic acids coding said viruses, pharmaceutical compositions comprising these viruses or nucleic acids and uses thereof. The invention also relates to methods for improving the immune response induced by an EHV vaccine against wild type EHV infections, methods for the prophylaxis and treatment of EHV infections and methods for distinguishing wild type EHV infected animals from animals treated with EHV's according to the invention.Type: GrantFiled: December 17, 2007Date of Patent: September 13, 2011Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Knut Elbers, Nikolaus Osterrieder, Christian Seyboldt
-
Publication number: 20110182865Abstract: Provided are compositions and methods for treatment and/or prophylaxis of EHV-I infections in horses. The compositions and methods effect treatment and/or prophylaxis of EHV-I infections through RNAi mediated inhibition of EHV-I gB and EHV-I Ori genes, which results in a reduction of the severity of neurological symptoms that are induced by EHV-I infection in horses, and/or a reduction in EHV-I viral shedding in the horses. Included are siRNAs or shRNAs that are designed to target EHV-I gB and EHV-I Ori helicase mRNAs. Also included are vectors encoding such shRNAs.Type: ApplicationFiled: February 9, 2009Publication date: July 28, 2011Inventors: Nikolaus Osterrieder, Gerlinde Van De Walle, Sarah T. Peters
-
Patent number: 7482441Abstract: The invention belongs to the field of animal health, in particular equine diseases caused by equine herpesvirus (EHV). The invention relates to artificial chromosomes comprising the genome of equine herpesviruses, methods of producing attenuated or virulent EHV with or without the insertion of foreign genes, EHV obtainable with said methods and pharmaceutical compositions comprising said viruses.Type: GrantFiled: February 5, 2004Date of Patent: January 27, 2009Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Nikolaus Osterrieder, Jens Rudolph
-
Patent number: 7309598Abstract: This invention relates to Equine Herpes Viruses (EHV) wherein the protein gM is essentially absent or modified and non-functional with respect to its immunomodulatory capacity. Further aspects of the invention relate to nucleic acids coding said viruses, pharmaceutical compositions comprising these viruses or nucleic acids and uses thereof. The invention also relates to methods for improving the immune response induced by an EHV vaccine against wild type EHV infections, methods for the prophylaxis and treatment of EHV infections and methods for distinguishing wild type EHV infected animals from animals treated with EHV's according to the invention.Type: GrantFiled: September 26, 2003Date of Patent: December 18, 2007Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Knut Elbers, Nikolaus Osterrieder, Christian Seyboldt
-
Publication number: 20060160202Abstract: The invention belongs to the field of animal health, in particular equine diseases caused by equine herpesvirus (EHV). The invention relates to artificial chromosomes comprising the genome of equine herpesviruses, methods of producing attenuated or virulent EHV with or without the insertion of foreign genes, EHV obtainable with said methods and pharmaceutical compositions comprising said viruses.Type: ApplicationFiled: February 5, 2004Publication date: July 20, 2006Applicant: Boehringer Ingelheim Vetmedica GmbHInventors: Nikolaus Osterrieder, Jens Rudolph
-
Publication number: 20060110403Abstract: The present invention relates to animal viruses such as animal herpesviruses as a vector for diagnostic, therapeutic and prophylactic delivery of foreign genes and nucleic acids to animals, human or primary cells derived thereof, respectively. By using said viruses, the prevention and treatment of infectious, autoimmune and tumor diseases as well as allergies and genetic disorders can be treated. The present invention relates further to procedures to efficiently transduce primary human cells with recombinant animal viruses in vitro and in vivo. The invention further relates to a kit useful (i) for diagnosis and monitoring of innate and adoptive immune responses as well as (ii) for gene therapy and (iii) immunization purposes.Type: ApplicationFiled: September 1, 2003Publication date: May 25, 2006Inventors: Martin Beer, Nikolaus Osterrieder, Jens Rudolph, Sascha Trapp, Ralf Wagner
-
Publication number: 20050084503Abstract: Provided is a method for producing a continuous cell line capable of supporting the growth of a Marek's disease virus (MDV) strain comprising infecting or transfecting a cell with a vector comprising a nucleic acid or fragment thereof of an MDV strain and culturing the cell or a progeny thereof under conditions suitable for the expression of the nucleic acid and propagation of the cell or progeny. The nucleic acid may comprise an MDV glycoprotein gE gene or functional fragment. Also provided is a method of generating, isolating, and/or maintaining a hypervirulent, very virulent, very virulent plus, virulent, and/or avirulent MDV strain comprising infecting a described cell with the MDV strain or strains, and culturing the cell under conditions suitable for the propagation of the cell and the generation, maintenance and isolation of the MDV strain or strains.Type: ApplicationFiled: August 4, 2004Publication date: April 21, 2005Inventors: Nikolaus Osterrieder, Daniel Schumacher
-
Publication number: 20040063095Abstract: This invention relates to Equine Herpes Viruses (EHV) wherein the protein gM is essentially absent or modified and non-functional with respect to its immunomodulatory capacity. Further aspects of the invention relate to nucleic acids coding said viruses, pharmaceutical compositions comprising these viruses or nucleic acids and uses thereof. The invention also relates to methods for improving the immune response induced by an EHV vaccine against wild type EHV infections, methods for the prophylaxis and treatment of EHV infections and methods for distinguishing wild type EHV infected animals from animals treated with EHV's according to the invention.Type: ApplicationFiled: September 26, 2003Publication date: April 1, 2004Applicant: Boehringer Ingelheim Vetmedica GmbHInventors: Knut Elbers, Nikolaus Osterrieder, Christian Seyboldt
-
Patent number: 6703231Abstract: This invention relates to Equine Herpes Viruses (EHV) wherein the protein gM is essentially absent or modified and non-functional with respect to its immunomodulatory capacity. Further aspects of the invention relate to nucleic acids coding said viruses, pharmaceutical compositions comprising these viruses or nucleic acids and uses thereof. The invention also relates to methods for improving the immune response induced by an EHV vaccine against wild type EHV infections, methods for the prophylaxis and treatment of EHV infections and methods for distinguishing wild type EHV infected animals from animals treated with EHV's according to the invention.Type: GrantFiled: February 16, 2001Date of Patent: March 9, 2004Assignee: Boehringer Ingelheim Vetmedica GmbHInventors: Knut Elbers, Nikolaus Osterrieder, Christian Seyboldt
-
Publication number: 20030198650Abstract: This invention relates to Equine Herpes Viruses (EHV) wherein the protein gM is essentially absent or modified and non-functional with respect to its immunomodulatory capacity. Further aspects of the invention relate to nucleic acids coding said viruses, pharmaceutical compositions comprising these viruses or nucleic acids and uses thereof. The invention also relates to methods for improving the immune response induced by an EHV vaccine against wild type EHV infections, methods for the prophylaxis and treatment of EHV infections and methods for distinguishing wild type EHV infected animals from animals treated with EHV's according to the invention.Type: ApplicationFiled: February 16, 2001Publication date: October 23, 2003Inventors: Knut Elbers, Nikolaus Osterrieder, Christian Seyboldt
-
Publication number: 20030059934Abstract: The invention belongs to the field of animal health, in particular equine diseases caused by equine herpesvirus (EHV). The invention relates to artificial chromosomes comprising the genome of equine herpesviruses, methods of producing attenuated or virulent EHV with or without the insertion of foreign genes, EHV obtainable with said methods and pharmaceutical compositions comprising said viruses.Type: ApplicationFiled: March 25, 2002Publication date: March 27, 2003Inventors: Nikolaus Osterrieder, Jens Rudolph